Lack of seroconversion of rheumatoid factor and anti-cyclic citrullinated peptide in patients with early inflammatory arthritis: A systematic literature review

Rheumatology

Volumn 50, Issue 2, 2011, Pages 311-316

  Barra, Lillian ^a   Pope, Janet ^a   Bessette, Louis ^b   Haraoui, Boulos ^c   Bykerk, Vivian ^d  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Anti cyclic citrullinated peptide; Early inflammatory arthritis; Early rheumatoid arthritis; Rheumatoid factor; Seroconversion; Systematic review; Undifferentiated inflammatory peripheral arthritis

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; RHEUMATOID FACTOR;

ARTHRITIS; ARTICLE; EARLY INFLAMMATORY ARTHRITIS; FOLLOW UP; HUMAN; JOINT SWELLING; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SEROCONVERSION; SEROPREVALENCE; SYSTEMATIC REVIEW;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; HUMANS; PEPTIDES, CYCLIC; RHEUMATOID FACTOR; TIME FACTORS;

EID: 78751680409     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq190     Document Type: Article

References (29)

1. Egsmose C, Lund B, Borg G et al. Patients with early arthritis benefit from early 2nd line therapy: 5 year follow-up of a prospective double blind placebo controlled study. J Rheumatol 1995;22:2208-13.
2. Van Der Heide A, Jacobs JWG, Bijlsma JWJ et al. The effectiveness of early treatment with 'second-line' anti-rheumatic drugs. A randomised controlled study. Ann Intern Med 1996;124:699-707.
3. Anderson JJ, Wells G, Verhoeven AC et al. Factors predicting response to treatment in rheumatoid arthritis. The importance of disease duration. Arthritis Rheum 2000; 43:22-9.
4. Jansen AL, Van Der Horst-Bruinsma I, Van Schaardenburg D et al. Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol 2002;29:2074-6.
5. Nishimura K, Sugiyama D, Kogata Y et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007;146:797-808.
6. Nell V, Machold KP, Stamm TA et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 2005;64:1731-6.
7. Visser H, le Cessie S, Vos K et al. How to diagnose rheumatoid arthritis early: a predictive model for persistent (erosive) arthritis. Arthritis Rheum 2002;46:357-65.
8. van der Helm-van Mil AHN, le Cessie S, van Dongen H et al. A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum 2007;56: 433-40.
9. Bas S, Genevay S, Meyer O, Gabay C. Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology 2003;42:677-80.
10. Scott DL. Prognostic factors in early rheumatoid arthritis. Rheumatology 2000;39(Suppl. 1):24-9.
11. Van Venrooij WJ, Zendman AJW, Pruijn GJM. Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis. Autoimmun Rev 2006;6:37-41.
12. Van Gaalen FA, Linn-Rasker SP, Van Venrooij WF et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004;50:709-15.
13. Visser K, Katchamart W, Loza E et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E initiative. Ann Rheum Dis 2009;68:1086-93.
14. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Third Symposium on Systematic Reviews: Beyond the Basics, July 3-5, 2000, Oxford, UK. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm.
15. Hulsemann JL, Zeidler H. Undifferentiated arthritis in an early synovitis out-patient clinic. Clin Exp Rheumatol 1995; 13:37-43.
16. Ates A, Karaaslan Y, Aksaray S. Predictive value of antibodies to cyclic citrullinated peptide in patients with early arthritis. Clin Rheumatol 2007;26:499-504.
17. Green M, Marzo-Ortega H, McGonagle D et al. Persistence of mild, early inflammatory arthritis. Arthritis Rheum 1999;42:2184-8.
18. Stockman A, Tait BD, Wolfe R et al. Clinical, laboratory and genetic markers associated with erosions and remission in patients with early inflammatory arthritis: a prospective cohort study. Rheumatol Int 2006;26:500-9.
19. Machold KP, Stamm TA, Eberl GJM et al. Very recent onset arthritis-clinical, laboratory, and radiological findings during the first year of disease. J Rheumatol 2002; 29:2278-87.
20. Carrier N, Fernandes AJ, Liang P et al. Fluctuations of rheumatoid factor, anti-CCP and anti-Sa over a period of 30 months in patients with polyarthritis of recent onset: association with severe outcomes. Arthritis Rheum 2006; 54:S818.
21. Narvaez J, Sirvent E, Narvaez JA et al. Usefulness of magnetic resonance imaging of the hand versus anticyclic citrullinated peptide antibody testing to confirm the diagnosis of clinically suspected early rheumatoid arthritis in the absence of rheumatoid factor and radiographic erosions. Semin Arthritis Rheum 2008;38:101-9.
22. Mjaavatten MD, van der Heijde D, Uhlig T et al. Should ACPA status be reassessed in patients with early arthritis: results from follow-up examinations in patients with arthritis of less than 16 weeks duration. Ann Rheum Dis 2009;68(Suppl. 3):374.
23. Cordonnier C, Meyer O, Palazzo E et al. Diagnostic value of anti-RA33, antikeratin antibody, antiperinuclear factor and antinuclear antibody in early rheumatoid arthritis: comparison with rheumatoid factor. Br J Rheumatol 1996; 35:620-4.
24. Vittecoq O, Jouen-Beades F, Krzanowska K et al. Rheumatoid factors, anti-filaggrin antibodies and low in vitro interleukin-2 and interferon-gamma production are useful immunological markers for early diagnosis of community cases of rheumatoid arthritis. A preliminary study. Joint Bone Spine 2001;68:144-53.
25. Flendrie M, Welsing PMJ, Van der Bif S, De Jong BAW, Van Venrooij WJ, Van Riel PLC. Longitudinal analysis of the relationship between anti-CCP antibodies and disease activity in patients with rheumatoid arthritis. EULAR 2004, http://www.abstracts2view.com/eular/view.php?nu=EULAR04L1_2004THU0272 (31 July 2009, date last accessed).
26. Nell VPK, Machold K, Hoeffler E, Steiner G, Smolen J. Development of autoantibodies in patients with very early arthritis-a follow up study. Ann Rheum Dis 2007; 66(Suppl. II):81.
27. Machold KP, Eberl G, Leeb BF, Nell V, Windisch B, Smolen JS. Early arthritis therapy: rationale and current approach. J Rheumatol 1998;32:97-103.
28. Guzian M, Carrier N, Cossette P et al. Baseline predictors of RA-associated antibodies (Abs) appearance (seroconversion) and disappearance (seroreversion) over 30 months in patients with early inflammatory polyarthritis (EPA). Canadian Rheumatology Association Annual Meeting 2009, http://www.rheum.ca/Resources/CRA-Mtgs/2009/abstracts_for_posting_2009.pdf (31 July 2009, date last accessed).
29. Quinn MA, Gough AK, Green MJ et al. Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology 2006;45: 478-80.